1033766-02-7

Basic information

• Product Name: N-{3-[1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7-hexahydro-pyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide
• Synonyms: N-{3-[1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7-hexahydro-pyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide
• CAS NO: 1033766-02-7
• Molecular Weight: 535.577
• Mol File: 1033766-02-7.mol

Chemical Properties

• CAS DataBase Reference: N-{3-[1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7-hexahydro-pyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{3-[1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7-hexahydro-pyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide(1033766-02-7)
• EPA Substance Registry System: N-{3-[1-(4-fluorobenzyl)-4-hydroxy-2-oxo-1,2,4a,5,6,7-hexahydro-pyrrolo[1,2-b]pyridazin-3-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide(1033766-02-7)

Safety Data

• Hazardous Substances Data: 1033766-02-7(Hazardous Substances Data)

Upstream product

• 54734-85-9 2-amino-5-nitrobenzenesulfonamide 
• 4533-95-3 5-nitro-2-chlorobenzenesulfonyl chloride 
• 43041-12-9 methyl pyrrolidine-2-carboxylate 
• 20896-44-0 2,5-diaminobenzenesulfonamide 
• 96-72-0 2-chloro-5-nitrobenzenesulfonamide 
• 96-73-1 2-chloro-5-nitro-benzenesulfonic acid 
• 1033766-37-8 methyl 1-aminopyrrolidine-2-carboxylate 
• 1000313-18-7 N-(4-(methanesulfonylamino)-2-sulfamoyl-phenyl)malonamic acid ethyl ester 
• 1000313-20-1 (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[e][1,2,4]thiadiazin-3-yl)-acetic acid 
• 1033766-28-7 1-(4-fluoro-benzylamino)pyrrolidine-2-carboxylic acid methyl ester 
• 691361-76-9 2-amino-5-(methanesulfonylamino)benzenesulfonamide 
• 459-57-4 4-fluorobenzaldehyde 

Relevant articles and documents

SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS

The invention is directed to saturated fused [1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase

Hexahydro-pyrrolo- and hexahydro-1H-pyrido[1,2-b]pyridazin-2-one analogs were discovered as a novel class of inhibitors of genotype 1 HCV NS5B polymerase. Among these, compound 4c displayed potent inhibitory activities in biochemical and replicon assays (IC50 (1b) 50 (1b) = 34 nM) as well as good stability towards human liver microsomes (HLM t1/2 = 59 min).